Phasebio Pharmaceuticals Inc(PHASQ)

Description: PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

---

Keywords: Biopharmaceutical Medication Organic Compounds Chemical Compounds U.S. Bankruptcy Court U.S. Bankruptcy Court For The District Of Delaware Pulmonary Arterial Hypertension Pulmonary Hypertension Cyclopropanes Invasive Procedure Adenosine Diphosphate Receptor Inhibitor Antiplatelet Drug Ticagrelor Pb1046

---

Home Page: phasebio.com

1 Great Valley Parkway
Malvern, PA 19355
United States
Phone: 610 981 6500

---

Officers

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)